Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations

Abstract

Since the beginning of hematopoietic stem cell harvesting from volunteer unrelated donors, ensuring donor safety has been a necessary goal of all parties involved in the process. As donation of BM or PBSCs is not in the interest of the donor's own physical health, donor registries and transplantation centers must take into account both medical and ethical aspects involved in the donation procedure. One of the principal goals leading to the formation of the World Marrow Donor Association (WMDA) was to establish internationally acceptable standards for all aspects of unrelated donor care.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Goldman JM . A special report: bone marrow transplants using volunteer donors—recommendations and requirements for a standardized practice throughout the world—1994 update. The WMDA Executive Committee. Blood 1994; 84: 2833–2839.

    CAS  PubMed  Google Scholar 

  2. Bakken R, van Walraven AM, Egeland T . Donor commitment and patient needs. Bone Marrow Transplant 2004; 33: 225–230.

    Article  CAS  PubMed  Google Scholar 

  3. Rosenmayr A, Hartwell L, Egeland T . Informed consent—suggested procedures for informed consent for unrelated haematopoietic stem cell donors at various stages of recruitment, donor evaluation, and donor workup. Bone Marrow Transplant 2003; 31: 539–545.

    Article  CAS  PubMed  Google Scholar 

  4. Duffy M, Coffey K . Confidentiality donor—patient. http://www.worldmarrow.org/fileadmin/WorkingGroups_Subcommittees/EWG/Confidentiality_EWG_2008.pdf. Accessed on 13 January 2010.

  5. http://www.jacie.org/portal/jacie/standards. Accessed on 13 January 2010.

  6. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9–14.

    Article  CAS  PubMed  Google Scholar 

  7. Egeland T, Lie J, Persson U, Raymond J, Muller C . Donor and liability insurance of donor registries, donor centers, and collection centers—recommendations. Bone Marrow Transplant 2004; 33: 467–470.

    Article  CAS  PubMed  Google Scholar 

  8. Heard P, Hartwell L, Greinix H . Patient consent to donor terms and transplant centre expectations. http://www.worldmarrow.org. Accessed on 13 January 2010.

  9. BSBMT. http://www.bsbmt.org/pages/64-Indications_Table, Accessed on 13 January 2010.

  10. Ljungman P, Bregni M, Brune M, Cornelissen J, Witte TD, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (e-pub ahead of print 6 July 2009).

  11. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    Article  CAS  PubMed  Google Scholar 

  12. Subsequent donations, clinical working group, link to projects. http://www.worldmarrow.org. Accessed on 13 January 2010.

  13. Cell dose survey response, clinical working group, link to projects. http://www.worldmarrow.org. Accessed on 13 January 2010.

  14. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  PubMed  Google Scholar 

  15. Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78; author reply 79–80.

    Article  PubMed  Google Scholar 

  16. Goldman JM, Madrigal JA, Pamphilon D . Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651–652.

    Article  CAS  PubMed  Google Scholar 

  17. McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D et al. Hematopoietic growth factors—use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008; 48: 2008–2025.

    Article  PubMed  Google Scholar 

  18. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L . Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.

    Article  CAS  PubMed  Google Scholar 

  19. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J . The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48: 1495–1501.

    Article  PubMed  Google Scholar 

  20. Tulpule S, Shaw BE, Makoni P, Little AM, Madrigal JA, Goldman JM . Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. Bone Marrow Transplant 2009; 44: 129–130.

    Article  CAS  PubMed  Google Scholar 

  21. Wanner M, Bochert S, Schreyer IM, Rall G, Rutt C, Schmidt AH . Losing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation. BMC Health Serv Res 2009; 9: 2.

    Article  PubMed  PubMed Central  Google Scholar 

  22. World Marrow Donor Association (WMDA) Guidelines for couriers and the transportation of haemopoietic progenitor cells (HPC-BM, apheresis and therapeutic cells- T Cells). http://www.worldmarrow.org/fileadmin/WorkingGroups_Subcommittees/DRWG/WMDA_Courier_and_Transportation_Guidelines.pdf. Accessed on 13 January 2010.

  23. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94–101.

    Article  PubMed  Google Scholar 

  24. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757–3763.

    Article  PubMed  Google Scholar 

  25. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604–3611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Carolyn Hurley, Effie Petersdorf, Lydia Foeken, Jeremy Chapman and members of the WMDA board for critical reading of the paper.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to B E Shaw.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shaw, B., Ball, L., Beksac, M. et al. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 45, 832–838 (2010). https://doi.org/10.1038/bmt.2010.2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.2

Keywords

  • WMDA
  • donor
  • safety

This article is cited by

Search

Quick links